Safety and Efficacy of Evolocumab in Addition to Optimal Stable Background Statin Therapy in Chinese Participants With Primary Hypercholesterolemia and Mixed Dyslipidemia

A phase 3 trial registered on ClinicalTrials.gov. The registry status is terminated. It enrolled 259 participants.

Also called NCT03433755

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 259 participants (enrolled count) (from the registry)
Sponsor
  • Amgen Registry lists this organization as the lead sponsor
Registry
  • NCT NCT03433755
Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
China (from the registry)
Registry status
  • Terminated (from the registry)

Technical summary

Registry record NCT03433755. Randomized; quadruple masking; primary purpose treatment. Start 2019-05-09 (actual); primary completion 2020-04-24 (actual). Results posted on 2021-08-20.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Safety and Efficacy of Evolocumab in Addition to Optimal Stable Background Statin Therapy in Chinese Participants With Primary Hypercholesterolemia and Mixed Dyslipidemia
Condition
Primary Hypercholesterolemia
Condition
Mixed Dyslipidemia
Intervention (Drug)
evolocumab
Intervention (Drug)
placebo
Lead sponsor
Amgen (class: industry)

Record details

Record id
cardio:ct-nct03433755
Content hash
d631a1f1d66ea9250627e251079a7ee932342eb612572bf5dcd5af72185dcc88